Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (6107)	2/14/2000 4:07:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

Thanks, Margie. Good luck, Peter Johnson! Please accept the CEO position at some/any company that I own shares of.

To: margie who wrote (6107)	2/16/2000 2:43:00 AM
From: billkirn	Respond to of 6136

Margie and Richard. Thanks for keeping us up to date. I feel sad, not sure exactly why, maybe the loss of Peter, his skill, talent, and magnetism represents a real loss for all of us in some way. If you hear that he is heading up another company please let us know. This biotech move over the last few months has been nothing short of spectacular and I am sure you have done well. My investments in HGSI, IDPH, RZYM, VICL, have performed extremely well. I did sell IMNR recently and invested the proceeds into CTII. Not sure if you two follow this company but my sense is that stem cell therapy will be significant over the years and it will take some time for this to develop. Good Luck. Bill

To: margie who wrote (6107)	5/23/2000 10:40:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

Chase Expands its Biotechnology Research Team NEW YORK--(BUSINESS WIRE)--May 23, 2000--The Chase Manhattan Corporation (NYSE: CMB - news) announced today that David T. Molowa, Ph. D. has joined Chase H&Q's equity research team, covering the biotechnology sector. Dr. Molowa joins as a managing director. In addition to Dr. Molowa, the firm also announced the addition of Maged Shenouda, Ronald Renaud and Alan Meyers to the firm's biotechnology research effort. ``These hires are a clear illustration of our commitment to this dynamic sector,'' says Douglas Braunstein, head of the firm's healthcare banking group and head of global mergers and acquisitions. ``We are extremely pleased that David, Maged, Ronald and Alan have joined the Chase team.'' Dr. Molowa will report to Todd Bakar, managing director and director of equity research. Mr. Shenouda, Mr. Renaud and Mr. Meyers will report to Mr. Molowa. ``Chase already has a top-notch research team in this sector with Rob Olan and Meg Malloy leading that effort,'' continued Todd Bakar. ``With our expanded team, we will be able to increase the breadth and depth of our research ability.'' Dr. Molowa joins Chase from Bear, Stearns & Company where he was senior managing director and responsible for the coverage of the life sciences technology companies. He has been selected for Institutional Investor's All-American Research team for the past seven years. Dr. Molowa holds a Ph. D. from the Medical College of Virginia, a M.B.A. from Rutgers University and a B.S. from the University of Richmond. Previous to joining Bear, Stearns, he was a senior research biochemist at Merck & Co. Mr. Shenouda joins Chase from Bear, Stearns & Company where he was a vice president in equity research covering the biotechnology and European pharmaceuticals industries for large cap companies. Mr. Shenouda holds a M.B.A. from Rutgers and a B.S. from St. John's University. Mr. Renaud and Mr. Meyers were previously at Bear, Stearns & Company in the biotechnology group in equity research.